B. Damiano

发表

Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.

S. Meegalla, C. Illig, D. Parks, 2011, Journal of medicinal chemistry.

Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.

C. Reynolds, B. Maryanoff, B. Damiano, 2009, Journal of medicinal chemistry.

Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment.

H. Almond, Jian Li, B. Maryanoff, 2007, Bioorganic & medicinal chemistry letters.

Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors

J. Qi, B. Damiano, Bing Hu, 2005, Peptides.

1,2,3,4-Tetrahydroquinoline-containing αvβ3 integrin antagonists with enhanced oral bioavailability

G. Leo, Dana L. Johnson, R. Kawahama, 2004 .

The Basis of Triggered Activity

M. Rosen, J. Moak, B. Damiano, 1985 .

RESEARCH PAPER Urotensin-II Induces Ear Flushing in Rats

R. Colburn, D. Stone, B. Damiano, 2007 .

RWJ-58259: a selective antagonist of protease activated receptor-1.

C. Derian, B. Maryanoff, B. Damiano, 2006, Cardiovascular drug reviews.

Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1.

W. Fung-Leung, K. Ngo, R. Ye, 1999, The Journal of pharmacology and experimental therapeutics.

Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo.

C. Derian, B. Damiano, P. Andrade-Gordon, 1998 .

Aza-bicyclic amino acid carboxamides as α4β1/α4β7 integrin receptor antagonists

B. Maryanoff, C. Schneider, B. Damiano, 2005 .

Chronic drug‐induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell‐derived cardiomyocytes

I. Kopljar, A. de Bondt, Hua-rong Lu, 2017, British journal of pharmacology.

3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.

J. Li, H. Ye, C. Derian, 2004, Bioorganic & medicinal chemistry letters.

Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.

C. Derian, A. Pandey, D. McComsey, 2001, Journal of medicinal chemistry.

Altered vascular injury responses in mice deficient in protease-activated receptor-1.

M. D'Andrea, B. Damiano, W. Cheung, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.

H. Ye, C. Derian, B. Maryanoff, 2007, Bioorganic & medicinal chemistry letters.

A novel fluorogenic substrate for the measurement of endothelial lipase activity

M. Connelly, I. Deckman, Shariff S Bayoumy, 2011, Journal of Lipid Research.

3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.

J. Li, H. Ye, C. Derian, 2004, Bioorganic & medicinal chemistry letters.

Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.

L. Minor, B. Maryanoff, B. Damiano, 2008, European journal of pharmacology.

Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates

M. D'Andrea, M. Nedelman, C. Derian, 2003, Journal of Pharmacology and Experimental Therapeutics.

Endothelial Lipase Is Localized to Follicular Epithelial Cells in the Thyroid Gland and Is Moderately Expressed in Adipocytes

M. Connelly, M. D'Andrea, Keli C Dzordzorme, 2012, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Increased Expression of Protease Activated Receptor-2 (PAR-2) in Balloon-Injured Rat Carotid Artery

M. D'Andrea, B. Damiano, L. de Garavilla, 1999, Thrombosis and Haemostasis.

Piperidine-containing β-arylpropionic acids as potent antagonists of αvβ3/αvβ5 integrins

Dana L. Johnson, B. Tounge, B. Maryanoff, 2004 .

CHARACTERIZATION OF RWJ‐351647, A NOVEL NONPEPTIDE VASOPRESSIN V2 RECEPTOR ANTAGONIST

B. Maryanoff, B. Damiano, L. de Garavilla, 2006, Clinical and experimental pharmacology & physiology.

Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.

M. D'Andrea, C. Derian, D. McComsey, 2001, The Journal of pharmacology and experimental therapeutics.

Pharmacology of RWJ 29009, a new potassium channel activator

R. Falotico, A. Gill, B. Damiano, 1994 .

Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis

M. Connelly, Zhihong Huang, E. Perzborn, 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Electrophysiologic effects of AHR 10718 on isolated cardiac tissues.

M. Rosen, B. Damiano, H. Le Marec, 1985, European journal of pharmacology.

Exploration of Potential Prodrugs of RWJ‐445167, an Oxyguanidine‐based Dual Inhibitor of Thrombin and Factor Xa

Tianbao Lu, M. Player, D. McComsey, 2006, Chemical biology & drug design.

Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo.

C. Derian, B. Damiano, W. Cheung, 1998, Canadian journal of physiology and pharmacology.

Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.

D. Hlasta, B. Maryanoff, C. Schneider, 2006, Journal of medicinal chemistry.

Carba‐nucleosides as Potent Antagonists of the Adenosine 5′‐Diphosphate (ADP) Purinergic Receptor (P2Y12) on Human Platelets

H. Ye, B. Maryanoff, B. Damiano, 2008, ChemMedChem.

Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa

B. Maryanoff, B. Damiano, L. de Garavilla, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.

S. Savvides, E. Di Cera, H. Almond, 2007, Journal of medicinal chemistry.

Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.

Robert H. Chen, D. McComsey, B. Maryanoff, 2007, Bioorganic & medicinal chemistry letters.

Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif.

B. Tomczuk, J. Spurlino, Hui-Sheng Huang, 2008, Bioorganic & medicinal chemistry letters.

1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists.

B. Maryanoff, B. Damiano, J. Mitchell, 2001, Bioorganic & medicinal chemistry letters.

Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.

B. Tomczuk, J. Spurlino, Tianbao Lu, 2010, Journal of medicinal chemistry.

Sustained electrical stimulation of the perforant path duplicates kainate-induced electrophysiological effects and hippocampal damage in rats

R. S. Sloviter, B. Damiano, 1981, Neuroscience Letters.

Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.

J A Mitchell, D. McComsey, B. Maryanoff, 1999, Journal of medicinal chemistry.

7-fluoroindazoles as potent and selective inhibitors of factor Xa.

Mark R Player, D. Parks, Yu-Kai Lee, 2008, Journal of medicinal chemistry.

Selection of a 2-azabicyclo[2.2.2]octane-based α4β1 integrin antagonist as an inhaled anti-asthmatic agent

C. Page, W. Abraham, B. Maryanoff, 2006 .

Pharmacology of bepridil.

A. Gill, S. Sit, B. Damiano, 1992, The American journal of cardiology.

Biological Consequences of Thrombin Receptor Deficiency in Mice

P. A. Peterson, W. Fung-Leung, R. Ye, 1996, Thrombosis and Haemostasis.

A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase

Narayanasami Sukumar, Claudia K Derian, Patricia Andrade-Gordon, 2005, Journal of Biological Chemistry.

Thrombin Regulation of Cell Function through Protease-Activated Receptors: Implications for Therapeutic Intervention

M. D'Andrea, C. Derian, B. Damiano, 2004, Biochemistry (Moscow).

A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic medication of behavioral effects in rats.

R. S. Sloviter, B. Damiano, J. Connor, 1980, The Journal of pharmacology and experimental therapeutics.

A thiocarbamate inhibitor of endothelial lipase raises HDL cholesterol levels in mice.

G. Leo, D. Hlasta, H. Xin, 2013, Bioorganic & medicinal chemistry letters.

Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042

B. D. Harris, D. McComsey, B. Maryanoff, 1996 .

Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.

B. Maryanoff, B. Damiano, J. Mitchell, 2001, Thrombosis research.

Effects of pacing on triggered activity induced by early afterdepolarizations.

M. Rosen, B. Damiano, 1984, Circulation.

On the relationship between kainic acid-induced epileptiform activity and hippocampal neuronal damage

R. S. Sloviter, B. Damiano, 1981, Neuropharmacology.

Torcetrapib Produces Endothelial Dysfunction Independent of Cholesteryl Ester Transfer Protein Inhibition

M. Connelly, F. Cools, D. Gallacher, 2009, Journal of cardiovascular pharmacology.

Hippocampal mediation of shaking behavior induced by electrical stimulation of the perforant path in the rat

B. Damiano, J. Connor, 1984, Brain Research.

Cardiovascular actions of thrombin receptor activation in vivo.

R. Falotico, B. Damiano, J. Mitchell, 1996, Journal of Pharmacology and Experimental Therapeutics.

Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans.

M. Connelly, P. Rothenberg, Atalanta Ghosh, 2012, International journal of clinical pharmacology and therapeutics.

Studies with an Orally Bioavailable αV Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats

S. Mousa, S. Bursell, A. Clermont, 2008, Journal of Pharmacology and Experimental Therapeutics.

Mer Receptor Tyrosine Kinase Signaling Participates in Platelet Function

Quan Li, C. Derian, B. Damiano, 2004, Arteriosclerosis, thrombosis, and vascular biology.

A Concise Synthesis of an Indenopyrrolidine-based Dual avb3/avb5 Integrin Antagonist

B. Tounge, B. Maryanoff, B. Damiano, 2004 .

A combined histochemical and double immunohistochemical labeling protocol for simultaneous evaluation of four cellular markers in restenotic arteries.

M. D'Andrea, B. Damiano, P. Andrade‐Gordon, 1999, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

Relative potency of amphetamine isomers in causing the serotonin behavioral syndrome in rats.

R. S. Sloviter, B. Damiano, J. Connor, 1980, Biological psychiatry.

Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.

A. Gibbs, M. Connelly, G. Kuo, 2009, Journal of medicinal chemistry.

Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis

M. Connelly, Zhihong Huang, E. Perzborn, 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates

M. D'Andrea, M. Nedelman, C. Derian, 2003, Journal of Pharmacology and Experimental Therapeutics.